Literature DB >> 11509485

Increased expression of peroxisome proliferator-activated receptor-alpha and -gamma in blood vessels of spontaneously hypertensive rats.

Q N Diep1, E L Schiffrin.   

Abstract

Peroxisome proliferator-activated receptors (PPARs) are a family of ligand-activated transcription factors that include PPAR-alpha, PPAR-gamma, and PPAR-delta. We hypothesized that PPAR expression in blood vessels could be reduced in hypertension to result in increased vascular growth and reduced apoptosis. We investigated the abundance of PPAR-alpha and PPAR-gamma in aorta and mesenteric arteries from young (6-week-old) and adult (16-week-old) spontaneously hypertensive rats (SHR) compared with age-matched control Wistar-Kyoto rats (WKY). mRNA levels of PPAR-alpha and PPAR-gamma were determined by reverse transcription-polymerase chain reaction. Protein expression was evaluated by Western blot and by immunohistochemistry. PPAR-gamma was expressed in aortic and mesenteric vascular smooth muscle cells (VSMCs) from intact tissue and cultured cells. PPAR-alpha was expressed in intact vascular tissue but was almost undetectable in cultured VSMCs. In mesenteric arteries from adult SHR, PPAR-alpha and PPAR-gamma mRNA levels were significantly greater than in WKY (P<0.05). In aorta, PPAR-alpha mRNA was significantly (P<0.05) more abundant in adult (but not in young) SHR than in WKY, whereas there was no difference in PPAR-gamma mRNA between WKY and SHR. PPAR-alpha and PPAR-gamma mRNA were greater in mesenteric arteries (P<0.05) in young and adult SHR than in WKY. Expression of PPAR-alpha and PPAR-gamma was similar in SHR and WKY in other tissues. In cultured mesenteric VSMCs, PPAR-gamma mRNA was 3-fold higher in SHR than in WKY. Immunohistochemistry demonstrated that PPAR-gamma resided constitutively in the cytoplasm in primary and low-passaged aortic and mesenteric VSMCs, whereas PPAR-alpha was almost undetectable. Thus, aorta and mesenteric resistance arteries from SHR in the prehypertensive and the established phase of hypertension exhibit increased expression of both PPAR isoforms, whereas other tissues do not. Changes (increases) in PPAR expression may play a compensatory role in the remodeling of blood vessels in SHR.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11509485     DOI: 10.1161/01.hyp.38.2.249

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  18 in total

Review 1.  PPAR-γ -- a possible drug target for complicated pregnancies.

Authors:  Fergus P McCarthy; Aoife C Delany; Louise C Kenny; Sarah K Walsh
Journal:  Br J Pharmacol       Date:  2013-03       Impact factor: 8.739

2.  Impaired peroxisome proliferator-activated receptor-gamma contributes to phenotypic modulation of vascular smooth muscle cells during hypertension.

Authors:  Lili Zhang; Peng Xie; Jingzhou Wang; Qingwu Yang; Chuanqin Fang; Shuang Zhou; Jingcheng Li
Journal:  J Biol Chem       Date:  2010-03-08       Impact factor: 5.157

Review 3.  The endocannabinoid system in cardiovascular function: novel insights and clinical implications.

Authors:  Salvador Sierra; Natasha Luquin; Judith Navarro-Otano
Journal:  Clin Auton Res       Date:  2017-12-08       Impact factor: 4.435

Review 4.  Does peroxisome proliferator-activated receptor-gamma (PPAR gamma) protect from hypertension directly through effects in the vasculature?

Authors:  Pimonrat Ketsawatsomkron; Christopher J Pelham; Séverine Groh; Henry L Keen; Frank M Faraci; Curt D Sigmund
Journal:  J Biol Chem       Date:  2010-02-03       Impact factor: 5.157

Review 5.  Aiming drug discovery at lysophosphatidic acid targets.

Authors:  Gabor Tigyi
Journal:  Br J Pharmacol       Date:  2010-09       Impact factor: 8.739

6.  Lysophosphatidic acid-induced arterial wall remodeling: requirement of PPARgamma but not LPA1 or LPA2 GPCR.

Authors:  Yunhui Cheng; Natalia Makarova; Ryoko Tsukahara; Huazhang Guo; E Shuyu; Patricia Farrar; Louisa Balazs; Chunxiang Zhang; Gabor Tigyi
Journal:  Cell Signal       Date:  2009-08-23       Impact factor: 4.315

7.  Colfibrate attenuates blood pressure and sodium retention in DOCA-salt hypertension.

Authors:  Yiqiang Zhou; Pengcheng Luo; Hsin-Hsin Chang; Hui Huang; Tianxin Yang; Zheng Dong; Cong-Yi Wang; Mong-Heng Wang
Journal:  Kidney Int       Date:  2008-07-02       Impact factor: 10.612

8.  Vascular smooth muscle cell-selective peroxisome proliferator-activated receptor-gamma deletion leads to hypotension.

Authors:  Lin Chang; Luis Villacorta; Jifeng Zhang; Minerva T Garcia-Barrio; Kun Yang; Milton Hamblin; Steven E Whitesall; Louis G D'Alecy; Y Eugene Chen
Journal:  Circulation       Date:  2009-04-13       Impact factor: 29.690

Review 9.  PPARs and the cardiovascular system.

Authors:  Milton Hamblin; Lin Chang; Yanbo Fan; Jifeng Zhang; Y Eugene Chen
Journal:  Antioxid Redox Signal       Date:  2009-06       Impact factor: 8.401

10.  Differential effects of short-term treatment with two AT1 receptor blockers on diameter of pial arterioles in SHR.

Authors:  Sébastien Foulquier; François Dupuis; Caroline Perrin-Sarrado; Katy Maguin Gatè; Pierre Leroy; Patrick Liminana; Jeffrey Atkinson; Christine Capdeville-Atkinson; Isabelle Lartaud
Journal:  PLoS One       Date:  2012-09-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.